trans-10,cis-12 conjugated linoleic acid prevents adiposity but not insulin resistance induced by an atherogenic diet in hamsters.
While conjugated linoleic acid (CLA) has received a great deal of attention as a supplement that can favourably modify body composition, its potential impact on insulin sensitivity has not received equal attention. The aim of the present work was to analyse the effects of trans-10,cis-12 CLA isomer on insulin sensitivity in hamsters fed an atherogenic diet. Hamsters were divided into three groups: one group was fed a chow diet (control) and the other two a semipurified atherogenic diet supplemented with 0.5% linoleic acid (LA) or trans-10,cis-12 CLA, respectively. Serum glucose, FFAs, insulin, leptin and adiponectin were measured using commercial kits. HOMA-IR was calculated using the formula of Matthews et al. PPARgamma mRNA was assessed in epididymal adipose tissue by reverse transcription-polymerase chain reaction (RT-PCR). After 6 weeks, atherogenic feeding produced an increase in body fat accumulation as compared with control feeding. The addition of trans-10,cis-12 CLA to the atherogenic diet avoided this feature. Atherogenic feeding also led to significantly higher serum concentrations of glucose, insulin, FFAs, as well as greater HOMA-IR values. trans-10,cis-12 CLA did not prevent these effects. No significant differences were found among experimental groups in serum leptin and adiponectin concentrations, nor in PPARgamma expression. In summary, although the addition of trans-10,cis-12 CLA to an atherogenic diet reduces fat accumulation, it does not improve the impairment of insulin action associated with this feeding. The maintenance of insulin resistance in hamsters fed the atherogenic CLA-enriched diet is probably due to the high serum FFA concentration observed in these animals.
Simón
Edurne
E
Department of Nutrition and Food Science, Faculty of Pharmacy, University of the Basque Country, Paseo de la Univrsidad, 7, 01006 Vitoria, Spain.
Macarulla
M Teresa
MT
Churruca
Itziar
I
Fernández-Quintela
Alfredo
A
Portillo
María P
MP
D052242:Adiponectin / Q000097:blood; D000273:Adipose Tissue / Q000737:chemistry; D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D006224:Cricetinae; D004032:Diet; D004036:Diet, Atherogenic; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage; D004822:Epididymis; D005230:Fatty Acids, Nonesterified / Q000097:blood; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D019787:Linoleic Acid / Q000008:administration & dosage; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage*; D008297:Male; D008647:Mesocricetus; D047495:PPAR gamma / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
D052242:Adiponectin; D001786:Blood Glucose; D004042:Dietary Fats, Unsaturated; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D020738:Leptin; D044243:Linoleic Acids, Conjugated; D047495:PPAR gamma; D012333:RNA, Messenger; C496197:trans-10,cis-12-conjugated linoleic acid; D019787:Linoleic Acid